Summit Therapeutics Inc. (SMMT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2022)
SMMT's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
SMMT Revenue Analysis (2014–2025)
As of March 1, 2026, Summit Therapeutics Inc. (SMMT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, SMMT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $56.4 million in 2018.
Revenue diversification analysis shows SMMT's business is primarily driven by License and Service (100%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY). Compare SMMT vs BNTX →
Peer Comparison
Compare SMMT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SMMTCurrent | $0 | - | - | - | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-108,355 | - | $-812,237,715 | - |
| 2024 | $0 | - | $-15,007,000 | - | $313K | - |
| 2023 | $0 | -100.0% | $-2,050,000 | - | $-89,736,000 | - |
| 2022 | $704K | -61.1% | $-1,810,000 | -257.0% | $-59,633,000 | -8467.0% |
| 2021 | $1.8M | +110.3% | $1.8M | 100.0% | $-86,186,000 | -4764.3% |
| 2020 | $860K | +40.6% | $860K | 100.0% | $-53,193,000 | -6185.2% |
| 2019 | $612K | -98.9% | $477K | 77.9% | $-22,624,000 | -3697.5% |
| 2018 | $56.4M | +222.5% | $56.4M | 100.0% | $5.4M | 9.6% |
| 2017 | $17.5M | +507.5% | $17.4M | 99.4% | $-36,560,000 | -209.0% |
| 2016 | $2.9M | +124.8% | $2.9M | 100.0% | $-31,065,000 | -1078.6% |
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SMMT vs AGIO
See how SMMT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SMMT's revenue growth accelerating or slowing?
SMMT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SMMT's long-term revenue growth rate?
Summit Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SMMT's revenue distributed by segment?
SMMT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.